Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 90Thoracic 11Gynecologic 10Head & Neck 8Genitourinary 7Dermatologic 5Breast 5Other solid neoplasm 2CNS 2Sarcoma 1

Conditions

Sarcoma 436Osteosarcoma 132Sarcoma, Ewing 89Melanoma 80Rhabdomyosarcoma 77Neoplasms 71Gastrointestinal Stromal Tumors 63Neuroblastoma 62Bone Neoplasms 62Breast Neoplasms 61Ovarian Neoplasms 60Colorectal Neoplasms 60Glioblastoma 55Neoplasm Metastasis 52Liposarcoma 52Dendritic Cell Sarcoma, Interdigitating 45Carcinoma, Non-Small-Cell Lung 43Leiomyosarcoma 42Gliosarcoma 42Stomach Neoplasms 41Pancreatic Neoplasms 41Lymphoma 36Uterine Cervical Neoplasms 35Sarcoma, Synovial 35Carcinoma, Renal Cell 35Rhabdoid Tumor 34Neurofibrosarcoma 34Lung Neoplasms 34Glioma 34Sarcoma, Kaposi 33

Interventions

ribociclib 1Fulvestrant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Sarcoma × 1 year × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡